BioArctic AB (publ) (FRA:B9A)

Germany flag Germany · Delayed Price · Currency is EUR
31.62
+1.34 (4.43%)
At close: Jan 28, 2026
65.55%
Market Cap4.50B +192.1%
Revenue (ttm)173.33M +1,046.5%
Net Income90.42M
EPS1.02
Shares Outn/a
PE Ratio49.72
Forward PE114.97
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume32
Open31.62
Previous Close30.28
Day's Range31.62 - 31.62
52-Week Range14.19 - 32.40
Betan/a
RSI53.86
Earnings DateFeb 18, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 122
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B9A
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements